We are live on ! Find out more
EDSA icon

Edesa Biotech

10 hedge funds and large institutions have $74K invested in Edesa Biotech in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.02% more ownership

Funds ownership: 0%0.02% (+0.02%)

17% less funds holding

Funds holding: 1210 (-2)

20% less capital invested

Capital invested by funds: $93K → $74K (-$19K)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
1
Closed
5
Calls
Puts
Net Calls
Net Calls Change

EDSA Hedge Fund Activity: Q2 2018 in Review

10 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q2 2018, worth a combined $74K — down 20% from $93K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EDSA and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $51.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $49K sold.

  • 10 institutional investors held Edesa Biotech (EDSA) as of Q2 2018, down from 12 in Q1 2018.
  • Funds reported $74K of Edesa Biotech stock for Q2 2018, down 20% quarter-over-quarter.
  • 3 funds opened new Edesa Biotech positions in Q2 2018 and 5 closed out, a net change of -2 holders.
  • The largest Edesa Biotech buyer in Q2 2018 was Raymond James Financial Services Advisors, an estimated $51.4K added.
  • The largest Edesa Biotech seller in Q2 2018 was Citadel Advisors, an estimated $49K sold.

Based on aggregated 13F filings for Q2 2018.